Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd (FREDUN) last traded at ₹1,450, a market capitalisation of ₹2,398 crore, on a P/E of 54.7. Over the past 52 weeks the stock has ranged between ₹377 and ₹1,600. Fredun Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹228 crore and net profit of ₹13 crore. Figures are as of 25 Aug 2026 and are not real time.
Fredun Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Fredun Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹228 cr, up 90.0% from ₹120 cr a year earlier. Net profit was ₹13 cr, up 85.7% year on year.
| ₹ crore | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 167 | 120 | 145 | 161 | 213 | 228 |
| Expenses | 0 | 150 | 103 | 123 | 135 | 184 | 196 |
| Operating profit | 0 | 17 | 17 | 22 | 26 | 29 | 33 |
| OPM % | — | 10% | 14% | 15% | 16% | 14% | 14% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 8 | 7 | 8 | 11 | 14 | 9 |
| Depreciation | 0 | 2 | 1 | 2 | 2 | 3 | 4 |
| Profit before tax | 0 | 7 | 9 | 13 | 14 | 11 | 21 |
| Tax % | — | 17% | 25% | 26% | 25% | 4% | 36% |
| Net profit | 0 | 6 | 7 | 9 | 10 | 11 | 13 |
| EPS (₹) | 0.00 | 4.23 | 4.77 | 6.64 | 6.51 | 6.57 | 7.96 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Fredun Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 454 | 635 | 748 |
| Operating profit | 52 | 91 | 110 |
| OPM % | 12% | 14% | 15% |
| Net profit | 20 | 33 | 44 |
| EPS (₹) | 13.90 | 19.89 | 27.68 |
TTM is the trailing twelve months to the most recent quarter.
Fredun Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 40%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 65%
- 10 Years
- 67%
- 5 Years
- 63%
- 3 Years
- 64%
- 1 Year
- 239%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 16%
Fredun Pharmaceuticals Ltd shareholding pattern
Promoters held 44.57% at Jul 2026, down from 48.93% at Sep 2025. FIIs 1.06% and DIIs 2.94%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 48.93% | 48.93% | 48.93% | 48.93% | 43.06% | 44.17% | 44.57% | 44.57% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.01% | 0.46% | 1.06% | 1.06% | 1.06% |
| DIIs | 1.59% | 1.59% | 1.59% | 1.61% | 3.48% | 2.83% | 2.94% | 2.94% |
| Public | 49.47% | 49.47% | 49.49% | 49.46% | 53.00% | 51.94% | 51.45% | 51.43% |
| No. of shareholders | 8,121 | 7,976 | 7,906 | 8,120 | 8,765 | 8,338 | 8,903 | 9,598 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Fredun Pharmaceuticals Ltd corporate filings
- Intimation regarding permission to trade and admission of Equity Shares to dealing on the National Stock Exchange of IndiaCompany Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has received formal permission to trade and admission of its…
Read the full analysis - Transcript of the Earnings Conference call held on 13th August, 2026 for Q1 FY27.Company Updatehigh impact
Cruxal's analysis: Fredun Pharmaceuticals Limited delivered robust Q1 FY27 results, with total income…
Read the full analysis - Statement of Deviation or Variation For the Quarter Ended June 30, 2026.Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has filed a statement confirming that there has been no deviation…
Read the full analysis - Monitoring Agency Report dated 14.08.2026Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has submitted a routine Monitoring Agency Report as part of its…
Read the full analysis - Audio Recording Q1 FY27 'Earnings Conference Call' of Fredun Pharmaceuticals Limited.Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has formally disclosed the audio recording of its Q1 FY27…
Read the full analysis - Intimation of Earnings Conference Call for the quarter Q1 of FY27.Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has formally announced an earnings conference call to…
Read the full analysis - Newspaper Advertisement of the Un-Audited Financial Results for Quarter ended 30th June, 2026Company Updatehigh impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has released its unaudited financial results for the…
Read the full analysis - Press Release issued by Fredun Pharmaceuticals LimitedCompany Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has filed a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended ....Board Meetinghigh impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has reported robust financial results for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Fredun Pharmaceuticals Ltd
Cruxal reads every Fredun Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.